- Home
- NRGV vs CRBU Comparison
NRGV vs CRBU Comparison
Compare NRGV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- CRBU
- Stock Information
- Founded
- NRGV 2017
- CRBU 2011
- Country
- NRGV United States
- CRBU United States
- Employees
- NRGV N/A
- CRBU N/A
- Industry
- NRGV Industrial Machinery/Components
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- NRGV Miscellaneous
- CRBU Health Care
- Exchange
- NRGV Nasdaq
- CRBU Nasdaq
- Market Cap
- NRGV 133.4M
- CRBU 93.0M
- IPO Year
- NRGV N/A
- CRBU 2021
- Fundamental
- Price
- NRGV $1.19
- CRBU $2.07
- Analyst Decision
- NRGV Buy
- CRBU Strong Buy
- Analyst Count
- NRGV 3
- CRBU 4
- Target Price
- NRGV $1.58
- CRBU $8.50
- AVG Volume (30 Days)
- NRGV 1.6M
- CRBU 1.9M
- Earning Date
- NRGV 08-07-2025
- CRBU 08-05-2025
- Dividend Yield
- NRGV N/A
- CRBU N/A
- EPS Growth
- NRGV N/A
- CRBU N/A
- EPS
- NRGV N/A
- CRBU N/A
- Revenue
- NRGV $46,974,000.00
- CRBU $9,918,000.00
- Revenue This Year
- NRGV $356.46
- CRBU $9.52
- Revenue Next Year
- NRGV $34.31
- CRBU N/A
- P/E Ratio
- NRGV N/A
- CRBU N/A
- Revenue Growth
- NRGV N/A
- CRBU N/A
- 52 Week Low
- NRGV $0.60
- CRBU $0.66
- 52 Week High
- NRGV $2.70
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- NRGV 65.05
- CRBU 55.77
- Support Level
- NRGV $0.75
- CRBU $2.03
- Resistance Level
- NRGV $1.64
- CRBU $2.66
- Average True Range (ATR)
- NRGV 0.13
- CRBU 0.22
- MACD
- NRGV 0.05
- CRBU 0.01
- Stochastic Oscillator
- NRGV 49.32
- CRBU 33.65
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.